Track topics on Twitter Track topics that are important to you
Soliris brought in net sales of $2.8 billion last year for Alexion, meaning it accounted for close to 90% of all sales for the company. It’s no wonder that the company is stacking its patent defences against any potential biosimilar encroachment onto its sales territory in the short term future.
Alexion announced that it had been granted three new patents for its lead product that will run through until 2027. This decade of breathing room would be particularly welcome, as the drug is a particular target for the creation of a biosimilar.
Original Article: Alexion moves to bolster patent protection of SolirisNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...